Compare Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Tax Managed Fund FTSE Developed Markets ETF vs Zimmer Biomet Holdings Inc — how do they compare? Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.47, while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| VEA | ZBH | |
|---|---|---|
52-Week High | $72.39 | $107.71 |
52-Week Low | $56.02 | $79.58 |
Market Cap | — | $17.36B |
Sector | — | Health |
Enterprise Value | — | $24.40B |
Dividend Yield | — | 1.07% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
